Colorectal microbicide design: Triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants

AIDS

Volumn 25, Issue 16, 2011, Pages 1971-1979

  Herrera, Carolina ^a,d   Cranage, Martin ^a   McGowan, Ian ^b   Anton, Peter ^c   Shattock, Robin J ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

colorectal microbicides; combinations; HIV 1; reverse transcriptase inhibitors; tissue explants

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DAPIVIRINE; EMTRICITABINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; TENOFOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CLADISTICS; CLINICAL EVALUATION; COLON; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFICACY; EX VIVO STUDY; EXPLANT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; MUTANT; PRIORITY JOURNAL; PROTEIN VARIANT;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; COLON; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUCOUS MEMBRANE; RECTUM; REVERSE TRANSCRIPTASE INHIBITORS; SEXUAL BEHAVIOR; TISSUE CULTURE TECHNIQUES;

EID: 80055005719     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834b3629     Document Type: Article

References (46)

1. Kalichman SC, Rompa D, Luke W, Austin J. HIV transmission risk behaviours among HIV-positive persons in serodiscordant relationships. Int J STD AIDS 2002; 13:677-682.
2. Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 1998; 148:88-96. (Pubitemid 28317549)
3. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol 1997; 146:350-357.
4. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150:306-311. (Pubitemid 29344958)
5. Anton PA, Elliott J, Poles MA, McGowan IM, Matud J, Hultin LE, et al. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 2000; 14:1761-1765.
6. Lapenta C, Boirivant M, Marini M, Santini SM, Logozzi M, Viora M, et al. Human intestinal lamina propria lymphocytes are naturally permissive to HIV-1 infection. Eur J Immunol 1999; 29:1202-1208. (Pubitemid 29164166)
7. Poles MA, Elliott J, Taing P, Anton PA, Chen IS. A preponderance of CCR5(R) CXCR4(R) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol 2001; 75:8390-8399. (Pubitemid 32768943)
8. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog 2010; 6:e1000890.
9. Klasse PJ, Shattock R, Moore JP. Antiretroviral drugbased microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008; 59:455-471. (Pubitemid 351287949)
10. McGowan I. Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis 2010; 23:26-31.
11. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
12. Ventuneac A, Carballo-Dieguez A, McGowan I, Dennis R, Adler A, Khanukhova E, et al. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men. AIDS Behav 2010; 14:618-628.
13. Anton P, Cranston R, Carballo-Dieguez A, et al. RMP-02/MTN-006: a phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDF. In: Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections; 27 February to 2 March 2011. Boston, MA: Hynes Convention Center; 2011
14. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local preexposure application of tenofovir gel. PLoS Med 2008; 5:e157.
15. Bennett DE, Zaidi I, Heneine W, et al. Prevalence of mutations associated with antiretroviral drug resistance among men and women newly diagnosed with HIV in 10 US cities, 1997-2001. Antiviral Ther 2003; 8:S133.
16. Briones C, Perez-Olmeda M, Rodriguez C, del Romero J, Hertogs K, Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr 2001; 26:145-150. (Pubitemid 32224185)
17. Chaix M, Descamps D, Mouajjah S, et al. French National Sentinel Survey of antiretroviral resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. Antiviral Ther 2003; 8:S137.
18. Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 2001; 26:266-273. (Pubitemid 32246557)
19. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394. (Pubitemid 34851830)
20. Mendoza C, Rodriguez C, Corral A, Gallego O, Romero J, Soriano V. Evidence for a different transmission efficiency of viruses with distinct drug-resistance genotypes. Antiviral Ther 2003; 8:S144.
21. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Coté P, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14:F17-F23. (Pubitemid 30116456)
22. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322:1087-1088.
23. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother 2009; 53:1797-1807.
24. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000; 74:8358-8367. (Pubitemid 30666686)
25. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:2855-2864. (Pubitemid 28175522)
26. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905. (Pubitemid 34535213)
27. Li Y, Hui H, Burgess CJ, Price RW, Sharp PM, Hahn BH, Shaw GM. Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. J Virol 1992; 66:6587-6600.
28. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and-defective viral genomes. J Virol 1991; 65:3973-3985.
29. Nunberg JH, Schleif WA, Boots EJ, O'Brien JA, Quintero JC, Hoffman JM, et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol 1991; 65:4887-4892.
30. Dupnik KM, Gonzales MJ, Shafer RW. Most multidrug-resistant HIV-1 reverse transcriptase clones in plasma encode functional reverse transcriptase enzymes. Antiviral Ther 2001; 6:42.
31. Gordon CJ, Muesing MA, Proudfoot AE, Power CA, Moore JP, Trkola A. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J Virol 1999; 73:684-694. (Pubitemid 28565413)
32. Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, McGowan I, et al. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 2006; 20:1237-1245. (Pubitemid 44030371)
33. Klasse PJ, Shattock RJ, Moore JP. Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med 2006; 3:e351.
34. Grivel JC, Margolis L. Use of human tissue explants to study human infectious agents. Nat Protoc 2009; 4:256-269.
35. Anton P, Adler A, Khanukhova E, et al. A phase 1 rectal safety and acceptability study of UC781 microbicide gel [abstract Y-147]. In: 16th Conference on Retroviruses and Opportunistic Infections; 2009, Boston, Massachusetts, USA.
36. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003; 1:25-34.
37. Figueiredo A, Moore KL, Mak J, Sluis-Cremer N, de Bethune MP, Tachedjian G. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog 2006; 2:e119.
38. Ma QF, Bathurst IC, Barr PJ, Kenyon GL. The observed inhibitory potency of 3'-azido-3'-deoxythymidine 5'-triphosphate for HIV-1 reverse transcriptase depends on the length of the poly(rA) region of the template. Biochemistry 1992; 31:1375-1379.
39. Quan Y, Rong L, Liang C, Wainberg MA. Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1. J Virol 1999; 73:6700-6707. (Pubitemid 29327852)
40. Villahermosa ML, Martinez-Irujo JJ, Cabodevilla F, Santiago E. Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides. Biochemistry 1997; 36:13223-13231. (Pubitemid 27473367)
41. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 2010; 5:e9310.
42. Margot NA, Waters JM, Miller MD. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother 2006; 50:4087-4095. (Pubitemid 44865153)
43. McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK, Miller MD. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr 2004; 37:1340-1350. (Pubitemid 39435048)
44. Miller M, Margot N, McColl D, Wrin T, Coakley D, Cheng A. Characterization of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF or stavudine in combination with lamivudine and efavirenz. Antiviral Therapy 2003; 8:S151.
45. Wei X, Liang C, Cotte M, Wainberg M. The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wildtype replication by attenuated viruses. AIDS 2002; 16:2391-2398. (Pubitemid 35471687)
46. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65RRM184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002; 46:3437-3446. (Pubitemid 35192909)